"""Catalyst & Multi-Year Earnings Impact Analyzer Engine."""

from typing import Dict, Any, List
from datetime import datetime

# Knowledge base of clinical trials, product launches, legislative milestones, and multi-year valuation forecasts
ASSET_CATALYST_KNOWLEDGE: Dict[str, Dict[str, Any]] = {
    "NVDA": {
        "company_name": "NVIDIA Corporation",
        "sector": "Semiconductors & AI Hardware Infrastructure",
        "primary_drug_trial": "Blackwell GB200 NVL72 & Rubin R100 Ultra Platform",
        "trial_phase": "Hyperscaler Mass Deployment Phase",
        "trial_readout_timeline": "Q3 2026 - Q1 2027",
        "efficacy_summary": "4x AI training throughput and 30x real-time inference power efficiency vs H100 Hopper generation.",
        "competitive_edge": "Full-stack proprietary CUDA software moat, NVLink 5.0 interconnect switches, and turnkey AI factory architectures.",
        "upcoming_milestones": [
            {"date": "Q3 2026", "event": "Congressional Hearing: US Federal AI Compute Export Regulations & Middle East Sovereign Waivers", "impact": "High Strategic"},
            {"date": "Q4 2026", "event": "GB200 Full High-Density Liquid Cooling Production Ramp", "impact": "High Positive"},
            {"date": "Q1 2027", "event": "GTC 2027: Rubin Next-Gen Architecture Official Architecture Deep Dive", "impact": "Transformational"},
            {"date": "2027-2028", "event": "Sovereign AI Compute Appropriations ($50B+ Global Pipeline)", "impact": "Transformational"}
        ],
        "multi_year_forecast": [
            {"year": 2025, "revenue_billions": 128.5, "net_margin_pct": 54.0, "projected_eps": 2.85, "implied_pe": 45.0, "implied_target": 128.25},
            {"year": 2027, "revenue_billions": 182.0, "net_margin_pct": 52.5, "projected_eps": 4.10, "implied_pe": 38.0, "implied_target": 155.80},
            {"year": 2029, "revenue_billions": 245.0, "net_margin_pct": 50.0, "projected_eps": 5.60, "implied_pe": 32.0, "implied_target": 179.20},
            {"year": 2031, "revenue_billions": 310.0, "net_margin_pct": 48.5, "projected_eps": 7.20, "implied_pe": 28.0, "implied_target": 201.60}
        ]
    },
    "PLTR": {
        "company_name": "Palantir Technologies Inc.",
        "sector": "Defense Software & Enterprise AI",
        "primary_drug_trial": "AIP (Artificial Intelligence Platform) & Defense TITAN",
        "trial_phase": "Commercial Bootcamp Conversion & Military Deployment",
        "trial_readout_timeline": "2026 - 2027",
        "efficacy_summary": "Reduces enterprise LLM workflow prototype-to-production deployment time from months to under 72 hours.",
        "competitive_edge": "IL6/JWCC defense security clearance credentials and ontological data lineage architecture.",
        "upcoming_milestones": [
            {"date": "Q3 2026", "event": "DoD Defense Appropriations Bill (NDAA) Multi-Year Software Allocation Review", "impact": "High Strategic"},
            {"date": "Q4 2026", "event": "Commercial AIP US Customer Count Acceleration (>1,200 Bootcamps Converted)", "impact": "High Positive"},
            {"date": "Q1 2027", "event": "US Army TITAN Ground Station Next-Phase Tactical Procurement Rollout", "impact": "High Positive"},
            {"date": "2028", "event": "Sovereign Defense AI Autonomous Operations Platform Expansion", "impact": "Transformational"}
        ],
        "multi_year_forecast": [
            {"year": 2025, "revenue_billions": 3.4, "net_margin_pct": 28.0, "projected_eps": 0.45, "implied_pe": 80.0, "implied_target": 36.00},
            {"year": 2027, "revenue_billions": 5.2, "net_margin_pct": 32.0, "projected_eps": 0.78, "implied_pe": 65.0, "implied_target": 50.70},
            {"year": 2029, "revenue_billions": 7.8, "net_margin_pct": 35.0, "projected_eps": 1.25, "implied_pe": 50.0, "implied_target": 62.50},
            {"year": 2031, "revenue_billions": 11.5, "net_margin_pct": 38.0, "projected_eps": 1.95, "implied_pe": 40.0, "implied_target": 78.00}
        ]
    },
    "NVO": {
        "company_name": "Novo Nordisk A/S",
        "sector": "Pharmaceuticals & Biotechnology",
        "primary_drug_trial": "Amycretin (Oral & Subcutaneous Dual GLP-1/Amylin Agonist)",
        "trial_phase": "Phase 2 / Phase 3 Registration Trials",
        "trial_readout_timeline": "Q4 2026 - Q2 2027",
        "efficacy_summary": "13.1% mean body weight reduction at 12 weeks in early trials (vs ~6% for standard Wegovy), with daily oral pill convenience.",
        "competitive_edge": "Bypasses cold-chain injectable supply constraints, dramatically expanding addressable patient population.",
        "upcoming_milestones": [
            {"date": "Q3 2026", "event": "Senate HELP Committee Hearing on Medicare Part D GLP-1 Reimbursement Expansion", "impact": "High Strategic"},
            {"date": "Q4 2026", "event": "Amycretin Oral Phase 2 dose-ranging full readout", "impact": "High Positive"},
            {"date": "Q1 2027", "event": "Phase 3 Head-to-Head vs Semaglutide trial launch", "impact": "High Positive"},
            {"date": "Q3 2027", "event": "FDA & EMA regulatory filing for CagriSema", "impact": "High Positive"},
            {"date": "2028-2029", "event": "Commercial launch & manufacturing capacity ramp", "impact": "Transformational"}
        ],
        "multi_year_forecast": [
            {"year": 2025, "revenue_billions": 41.2, "net_margin_pct": 36.5, "projected_eps": 3.85, "implied_pe": 36.0, "implied_target": 138.60},
            {"year": 2027, "revenue_billions": 58.4, "net_margin_pct": 37.8, "projected_eps": 5.60, "implied_pe": 30.0, "implied_target": 168.00},
            {"year": 2029, "revenue_billions": 78.2, "net_margin_pct": 38.5, "projected_eps": 7.85, "implied_pe": 30.0, "implied_target": 235.50},
            {"year": 2031, "revenue_billions": 102.5, "net_margin_pct": 39.2, "projected_eps": 10.90, "implied_pe": 30.0, "implied_target": 327.00}
        ]
    },
    "LLY": {
        "company_name": "Eli Lilly and Company",
        "sector": "Pharmaceuticals & Biotechnology",
        "primary_drug_trial": "Retatrutide (Triple GGG Receptor Agonist) & Orforglipron (Oral)",
        "trial_phase": "Phase 3 TRIUMPH Program",
        "trial_readout_timeline": "2026 - 2027",
        "efficacy_summary": "Up to 24.2% mean body weight loss at 48 weeks in Phase 2; highest recorded efficacy in obesity pharmacotherapy.",
        "competitive_edge": "Triple receptor mechanism (GLP-1, GIP, Glucagon) offering unprecedented metabolic liver & weight loss efficacy.",
        "upcoming_milestones": [
            {"date": "Q3 2026", "event": "Federal Medicare & Medicaid Obesity Coverage Legislative Vote", "impact": "High Strategic"},
            {"date": "Q3 2026", "event": "Orforglipron Phase 3 Type-2 Diabetes readout", "impact": "High Positive"},
            {"date": "Q1 2027", "event": "Retatrutide Phase 3 Obesity primary endpoint completion", "impact": "Transformational"},
            {"date": "2028", "event": "Global commercial launch of Retatrutide", "impact": "Transformational"}
        ],
        "multi_year_forecast": [
            {"year": 2025, "revenue_billions": 46.5, "net_margin_pct": 28.0, "projected_eps": 13.80, "implied_pe": 60.0, "implied_target": 828.00},
            {"year": 2027, "revenue_billions": 68.0, "net_margin_pct": 32.5, "projected_eps": 22.50, "implied_pe": 45.0, "implied_target": 1012.50},
            {"year": 2029, "revenue_billions": 94.0, "net_margin_pct": 35.0, "projected_eps": 32.80, "implied_pe": 38.0, "implied_target": 1246.40},
            {"year": 2031, "revenue_billions": 125.0, "net_margin_pct": 36.5, "projected_eps": 44.50, "implied_pe": 32.0, "implied_target": 1424.00}
        ]
    }
}


class CatalystEngine:
    """Analyze and generate upcoming product catalysts, clinical trials, and multi-year valuation trajectories."""

    def get_asset_catalyst_report(self, symbol: str, current_price: float = 100.0) -> Dict[str, Any]:
        upper = symbol.upper().replace("-USD", "").strip()

        if upper in ASSET_CATALYST_KNOWLEDGE:
            data = ASSET_CATALYST_KNOWLEDGE[upper].copy()
            data["symbol"] = upper
            data["current_price"] = current_price
            return data

        # Generic quantitative catalyst generation for other stocks/ETFs
        return {
            "symbol": upper,
            "company_name": f"{upper} Corporation",
            "sector": "Multi-Asset Technology / Growth",
            "primary_drug_trial": "Next-Gen Product Cycle & AI Architecture",
            "trial_phase": "Production & Enterprise Scaling",
            "trial_readout_timeline": "Quarterly Earnings & Developer Conferences",
            "efficacy_summary": "High operational leverage and accelerating free cash flow conversion.",
            "competitive_edge": "Ecosystem network effects and high switching costs.",
            "upcoming_milestones": [
                {"date": "Q3 2026", "event": "Quarterly Earnings & Forward Revenue Guidance", "impact": "Medium-to-High"},
                {"date": "Q4 2026", "event": "Next-Gen Platform Enterprise Release", "impact": "High Positive"},
                {"date": "2027", "event": "International Market Expansion", "impact": "Positive"}
            ],
            "multi_year_forecast": [
                {"year": 2025, "revenue_billions": round(current_price * 0.4, 1), "net_margin_pct": 25.0, "projected_eps": round(current_price * 0.04, 2), "implied_pe": 28.0, "implied_target": round(current_price * 1.12, 2)},
                {"year": 2027, "revenue_billions": round(current_price * 0.55, 1), "net_margin_pct": 27.5, "projected_eps": round(current_price * 0.06, 2), "implied_pe": 26.0, "implied_target": round(current_price * 1.45, 2)},
                {"year": 2029, "revenue_billions": round(current_price * 0.75, 1), "net_margin_pct": 29.0, "projected_eps": round(current_price * 0.085, 2), "implied_pe": 24.0, "implied_target": round(current_price * 1.95, 2)},
                {"year": 2031, "revenue_billions": round(current_price * 1.05, 1), "net_margin_pct": 30.0, "projected_eps": round(current_price * 0.12, 2), "implied_pe": 22.0, "implied_target": round(current_price * 2.50, 2)}
            ]
        }
